Adherium has announced the appointment of Jane Lapon as Head of Global Market Access & Reimbursement, where she will be responsible for ensuring reimbursement for the Hailie inhaler monitoring platform. Lapon was most recently VP of Global Market Access at Boston Scientific and has previously held executive positions in global market access roles at BTG (which … [Read more...] about Adherium appoints Jane Lapon as Head of Global Market Access & Reimbursement
News
Altavant Sciences acquires Onspira Therapeutics
Altavant Sciences has announced its acquisition of Onspira Therapeutics, which apparently had a single candidate in its pipeline: OSP-101, an inhaled interleukin-1 receptor antagonist. In August 2018, the FDA granted Orphan Drug designation to OSP-101 for the treatment of bronchiolitis obliterans syndrome (BOS). According to Altavant, the deal included an upfront … [Read more...] about Altavant Sciences acquires Onspira Therapeutics
AI Therapeutics provides update on inhaled rapamycin
AI Therapeutics (formerly LAM Therapeutics) said that it is seeking a partner to advance its LAM-001 inhaled rapamycin into Phase 3 trials for the treatment of lymphangioleiomyomatosis (LAM disease) and into Phase 2 for the treatment of pulmonary arterial hypertension (PAH). The company said that LAM-001 has been granted Orphan Drug designation for LAM in Europe and … [Read more...] about AI Therapeutics provides update on inhaled rapamycin
Afrezza to be launched in Brazil
According to MannKind Corporation, Brazil's Drug Market Regulation Chamber (CMED) has approved the proposed pricing for Afrezza inhaled insulin, and the Afrezza DPI is set to launch in Brazil within the next week. The Brazilian Health Regulatory Agency (ANVISA) approved Afrezza for the treatment of diabetes in June 2019. In June 2017, MannKind announced that it … [Read more...] about Afrezza to be launched in Brazil
Merxin launches DPI for generic Ellipta products
UK-based device company Merxin has officially launched its new MRX006 multidose DPI, which has dual cavities and is designed specifically for triple therapies such as generic versions of Trelegy Ellipta. The company introduced the new DPI at DDL 2019 and reported that it fielded numerous inquiries about the device. In 2019, the FDA indicated that Merxin's MRX001 … [Read more...] about Merxin launches DPI for generic Ellipta products
Impopharma acquired by Rubicon Research
Canadian CRO Impopharma, which specializes in OINDP analysis and development, has been acquired by Rubicon Research, Rubicon said. Impopharma's Concord, ON facility will become Rubicon's Nasal and Pulmonary Center of Excellence. Impopharma's services included testing and development of nasal sprays, MDIs, and DPIs. According to Rubicon, the company expects the … [Read more...] about Impopharma acquired by Rubicon Research
Seelos Therapeutics sets Type C meeting with FDA regarding SLS-002 intranasal racemic ketamine
Seelos Therapeutics said that it has scheduled a Type C meeting with the FDA for March 2020 regarding a Phase 3 trial of its SLS-002 intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD). The FDA granted Fast Track designation to SLS-002 in November 2019. According to the … [Read more...] about Seelos Therapeutics sets Type C meeting with FDA regarding SLS-002 intranasal racemic ketamine
Pulmatrix announces collaboration with Nocion Therapeutics
Two months after announcing the appointment of Nocion Therapeutics CEO Rick Batycky to its board, Pulmatrix has announced a deal with Nocion to look at the use of Pulmatrix's iSPERSE particle engineering technology for development of inhaled formulations of Nocion drugs. According to the Nocion web site, the company's lead candidate targets refractory chronic cough. … [Read more...] about Pulmatrix announces collaboration with Nocion Therapeutics
ATAI Life Sciences partners with Neuronasal on intranasal N-acetylcysteine for concussion
ATAI Life Sciences has announced a deal with US-based Neuronasal Inc. for development of intranasal N-acetylcysteine (NAC) for the treatment of mild traumatic brain injury (mTBI, or concussion). ATAI said that it expects initiation of a pilot study in healthy volunteers in February 2020. According to a Neuronasal presentation, the drug would be delivered via the … [Read more...] about ATAI Life Sciences partners with Neuronasal on intranasal N-acetylcysteine for concussion
Pulmatrix announces license agreement with J&J’s Lung Cancer Initiative
According to Pulmatrix, the Lung Cancer Initiative at Johnson & Johnson will pay $7.2 million up front plus a $2 million milestone payment for an option "to access a portfolio of narrow spectrum kinase inhibitors intended for development in lung cancer interception." The $2 million milestone payment will be due on completion of a Phase 1b study of RV1162/PUR1800 … [Read more...] about Pulmatrix announces license agreement with J&J’s Lung Cancer Initiative